Zenas BioPharma’s stock climbed 33% following a positive mid-phase trial readout for its lead candidate, obexelimab, in relapsing multiple sclerosis (RMS). During the Phase II MoonStone study ...
Glycolysis-dependent Sulfur Metabolism Orchestrates Morphological Transitions and Virulence in Fungi.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback